The Latest in CLL

Ibrutinib-venetoclax found highly active in hard-to-treat CLL

July 22, 2019

Acalabrutinib extends PFS in advanced CLL

July 11, 2019

Ibrutinib tops chlorambucil against CLL

July 10, 2019

Hedgehog signaling offers prognostic, therapeutic potential in CLL

June 25, 2019

Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapy

June 7, 2019

Venetoclax plus ibrutinib appears to suit elderly and high-risk patients with CLL

May 29, 2019

Genetic analysis identifies prognostic markers in CLL

May 28, 2019

FDA approves venetoclax/obinutuzumab combo for CLL

May 15, 2019

Idelalisib shows long-term safety, efficacy for relapsed CLL

April 26, 2019

Bendamustine/rituximab combo proves viable for comorbid CLL

April 10, 2019

Ibrutinib sustained responses in refractory CLL in long-term follow-up

March 27, 2019

Venetoclax and obinutuzumab induces deep responses in CLL

March 18, 2019

Short telomeres predict poorer response to chemo in CLL

March 15, 2019

CLL, GVHD may raise risk for skin cancer after allo-HCT

February 28, 2019

Targeted triplet shows potential for B-cell cancers

February 14, 2019